PIK3CA and non-small cell lung carcinoma: It was evaluated in the phase II BASALT-1 trial in patients with relapsed NSCLC with PIK3CA or PTEN alterations, but only two patients had partial responses and the second stage of the study did not proceed given its futility [78].